FRIDAY, June 30, 2017 (HealthDay News) -- For adults with ischemic or nonischemic cardiomyopathy, implantable cardioverter defibrillator (ICD) therapy is associated with reduced incidence of sudden and all-cause death compared with conventional care, according to a review published online June 27 in the Annals of Internal Medicine.
Michalina Kolodziejkczak, M.D., from Nicolaus Copernicus University in Bydgoszcz, Poland, and colleagues compared ICD therapy with conventional care for the primary prevention of death using data from 11 trials involving 8,716 patients.
The researchers observed an overall reduction in all-cause mortality, from 28.26 percent with conventional care to 21.37 percent with ICD therapy (hazard ratio [HR], 0.81; 95 percent confidence interval [CI], 0.70 to 0.94; P = 0.043). The reduction was of similar magnitude in the cohorts with nonischemic (HR. 0.81; 95 percent CI, 0.72 to 0.91) and ischemic disease (HR, 0.82; 95 percent CI, 0.63 to 1.06). There was a decrease in the rate of sudden death, from 12.15 percent with conventional care to 4.39 percent with ICD therapy (HR, 0.41; 95 percent CI, 0.30 to 0.56); the reduction was of similar magnitude for patients with ischemic (HR, 0.39; 95 percent CI, 0.23 to 0.68) and nonischemic disease (HR, 0.44; 95 percent CI, 0.17 to 1.12).
"Overall, primary prevention with ICD therapy versus conventional care reduced the incidence of sudden and all-cause death," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
